Abstract
Antimicrobial peptides (AMPs) are critical components of innate immunity in animals and plants, exhibiting thrilling prospectives as alternatives to traditional antibiotics due to their ability to combat pathogens without leading to resistance. Among these, Human Neutrophil Peptide-1 (HNP-1), primarily produced by human neutrophils, exhibits broad-spectrum antimicrobial activity against bacteria and viruses. However, the clinical application of HNP-1 has been hampered by challenges associated with mass production and inconsistent understanding of its bactericidal mechanisms. This review explores the structure and function of HNP-1, discussing its gene expression, distribution, immune functions and the regulatory elements controlling its production, alongside insights into its antimicrobial mechanisms and potential clinical applications as an antimicrobial agent. Furthermore, the review highlights the biosynthesis of HNP-1 using microbial systems as a cost-effective alternative to human extraction and recent studies revealing HNP-1's endogenous bactericidal mechanism. A comprehensive understanding of HNP-1's working mechanisms and production methods will pave the way for its effective clinical utilization in combating antibiotic-resistant infections.